Navigation Links
BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
Date:1/19/2012

FREDERICK, Md., Jan. 19, 2012 /PRNewswire/ -- BioElectronics Corporation. (OTC-PINK: BIEL), the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced the acceptance for publication of an article in the peer reviewed journal The Journal of Foot and Ankle Surgery. The article documents the clinical trial results of BioElectronics' study of its medical device on plantar fasciitis.

Plantar fasciitis, or heel pain, is a very common complaint which affects up to two million people in the United States yearly, in a multi-million dollar treatment market. Plantar fasciitis heel pain, with the current treatment options, can persist up to one or two years and can be extremely painful and debilitating. 

"With this published clinical trial, which was a placebo controlled, randomized and double blind study, BioElectronics is demonstrating that its patented pulsed radiofrequency electromagnetic field therapy medical device offers a rapid and economical resolution of the heel pain, and consequently is a significant advancement over current treatment options," said Ian Rawe, PhD, BioElectronics Director of Clinical Research. "The publication of these results will help introduce to the medical community a drug-free treatment featuring our unique medical device as an orthopedic pain therapy. We anticipate strong interest which will lead to expanded clinical study on a variety of orthopedic conditions." 

BioElectronics is currently conducting a second clinical study on plantar fasciitis using its revolutionary 'Smart Insole,' which provides a simple, 24-hour treatment option. With this new study, BioElectronics anticipates that it is moving toward making its therapy the treatment of choice in people suffering from plantar fasciitis.

About BioElectronics Corporation

BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:
Paul Knopick
E & E Communications
(949) 707-5365
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
2. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
5. BioElectronics Announces Major Clinical Trials
6. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
7. Incisive Surgical Announces Breakthrough Peer Review Clinical Study
8. Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies
9. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
11. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition ... to their offering. ... The global oxygen therapy devices market to grow at a ... report, Global Oxygen Therapy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/23/2017)... 2017 A research report by Mordor ... to reach USD 7.2 billion by the end of 2021 ... a procedure in which a sample is preserved prior to ... procedures since the methods are often allowing repeated testing. The ... most shared procedures in the lab. In many life science ...
(Date:3/23/2017)... -- Newborns are highly vulnerable to infections and ... young immune systems typically mount weak antibody responses. ... strong vaccine responses in newborn animals, including monkeys ... — by adding compounds known as adjuvants that ... they also describe improved adjuvant formulations that could ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council on ... The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at ... in the U.S. It argues that this higher bar should be set by states, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... City Convention Center at 10 North Broadway Avenue, will be an educational and ... relevant, practical instruction in the management of chronic pain. , Oklahoma is in ...
Breaking Medicine News(10 mins):